MELBOURNE, Australia, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar on The Watchlist, to be held on Tuesday, 14th November, 2023, 1:00pm AEDT/10:00am AWST.
CEO Steven Lydeamore will provide an overview and update on the business and upcoming milestones.
Following the presentation, attendees will have the opportunity to ask questions directly to Mr Lydeamore during a moderated Q & A session.
This webinar can be viewed live via zoom & you register via the link below.
Zoom: https://share.hsforms.com/1ccfJimCATYqzCkvIKIC7VAd16zr
A recorded copy of the webinar and presentation will be available on the Company’s website following the event.
Authorised for release by the Board of Immuron Limited.
| COMPANY CONTACT: Steven Lydeamore Chief Executive Officer Ph: +61 (0)3 9824 5254 This email address is being protected from spambots. You need JavaScript enabled to view it. |
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN) is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
For more information visit: http://www.immuron.com
| Last Trade: | US$1.57 |
| Daily Change: | 0.02 1.29 |
| Daily Volume: | 1,034,952 |
| Market Cap: | US$10.910M |
December 03, 2025 November 05, 2025 October 13, 2025 October 08, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
